Ulcerative Colitis Clinical Trials in Phoenix

Showing 581-587 of 587 trials

Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

NCT00345774

This study is being conducted to see if PRX-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.

Pulmonary HypertensionChronic Obstructive Pulmonary Disease

Epix Pharmaceuticals, Inc.72 participantsStarted Jun 2006

Anniston, Alabama, United States • Phoenix, Arizona, United States • Sacramento, California, United States +16 more locations

COMPLETEDPhase 3108 miles

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

NCT00642512

The primary purpose of the study is to determine the efficacy of oral dronabinol versus standard ondansetron antiemetic therapy in preventing delayed-onset chemotherapy-induced nausea and vomiting (CINV) or retching by measuring the incidence of total response of nausea and vomiting and/or retching following administration of moderate-to-high emetogenic chemotherapeutic agents.

Chemotherapy Induced Nausea and Vomiting

Solvay Pharmaceuticals64 participantsStarted Jul 2003

Tucson, Arizona, United States • Anaheim, California, United States • Fountain Valley, California, United States +40 more locations

Safety and Effectiveness of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease

Dronabinol Versus Standard Ondansetron Antiemetic Therapy in Preventing Delayed-Onset Chemotherapy-Induced Nausea and Vomiting

Ulcerative Colitis Trials in Other Cities

Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)

Basiliximab in Moderate to Severe Ulcerative Colitis

CORE: A Study of OPC-6535 With Asacol® in Maintaining Ulcerative Colitis (UC) Remission

Additivity Study: Additive Effect on Eye Pressure of Azopt and Alphagan P to Travatan

Phase 2 Study of the Safety and Efficacy of UK-500,001 in Adult Patients With COPD

Other Conditions in Phoenix